Skip to main content
. 2012 Jan 17;30(6):2352–2363. doi: 10.1007/s10637-011-9789-z

Fig. 2.

Fig. 2

Pre- and post-treatment computed tomography: a 70-year-old patient with NSCLC (Table 4, patient No. 1) (a) receiving dacomitinib at 15 mg QD; and a 66-year-old patient with NSCLC (Table 4, patient No. 4) (b) receiving dacomitinib at 30 mg QD